Our product areas

We prevent and treat disease with specialty medicines, vaccines and general medicines. We focus on the science of the immune system and the use of new platform and data technologies, investing in four core therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; infectious diseases. Our Ahead Together strategy means intervening early to prevent and change the course of disease, helping to protect people and support healthcare systems. We’re confident in our future. With our strong momentum and improving outlook for sustained growth through the decade, we're confident in our ability to deliver human health impact at scale, worldwide.

Specialty medicines are prescribed by specialist healthcare practitioners. Our portfolio of specialty medicines prevents and treats diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. We’re leaders in infectious diseases and HIV innovation and we’re building our positions in immunology and oncology.

Vaccines help protect people from infectious diseases at every stage of life. Our portfolio of marketed vaccines is the broadest in the industry. It includes more than 20 vaccines that help protect people around the world from a range of diseases and infections throughout their lives. We are proud of the impact our vaccines continue to have on the health of hundreds of millions of people around the world.

General medicines are usually prescribed in primary care or community settings by general healthcare practitioners. General medicines include inhalers for asthma and COPD to antibiotics. Every day, our general medicines make life better for millions of people all over the world.

Our operations span the value chain from identifying, researching, developing and testing groundbreaking discoveries, to regulatory approval, manufacturing and commercialisation. Getting our medicines and vaccines to patients who need them is critical to how we improve health around the world. Our global network of 37 medicines and vaccines manufacturing sites enabled us to produce and deliver 2.1 billion packs of medicines and doses of vaccines in 2024.

We make sure that products are manufactured as efficiently as possible and meet the strictest quality standards. The highest quality standards are ensured during each step of the vaccine production process, including vaccine components, facilities and equipment, people training, qualification, certification and storage. Each of our vaccines products is produced manufactured to the same quality standard, regardless of where in the world the vaccine it will be used.

We've built an agile network, with the capacity and capability to bring the next generation of medicines to patients all over the globe.